Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGC NASDAQ:EPRX NASDAQ:FULC NASDAQ:KLRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.07-1.8%$1.07$0.84▼$2.38$440.49M0.7813.93 million shs6.76 million shsEPRXEupraxia Pharmaceuticals$7.16-5.2%$7.31$3.67▼$9.32$456.28M1.19164,253 shs131,957 shsFULCFulcrum Therapeutics$7.11-1.9%$7.51$5.65▼$15.74$483.09M3.02755,643 shs501,071 shsKLRSKalaris Therapeutics$5.22+8.1%$6.58$2.14▼$11.88$111.05M0.1598,052 shs171,592 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth-1.83%-5.31%-1.83%-0.93%-24.11%EPRXEupraxia Pharmaceuticals-5.17%-4.15%-0.83%-14.96%+81.73%FULCFulcrum Therapeutics-1.93%+3.34%-10.23%-33.11%+26.29%KLRSKalaris Therapeutics+8.07%+1.36%-10.31%-39.65%+521,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.07-1.8%$1.07$0.84▼$2.38$440.49M0.7813.93 million shs6.76 million shsEPRXEupraxia Pharmaceuticals$7.16-5.2%$7.31$3.67▼$9.32$456.28M1.19164,253 shs131,957 shsFULCFulcrum Therapeutics$7.11-1.9%$7.51$5.65▼$15.74$483.09M3.02755,643 shs501,071 shsKLRSKalaris Therapeutics$5.22+8.1%$6.58$2.14▼$11.88$111.05M0.1598,052 shs171,592 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth-1.83%-5.31%-1.83%-0.93%-24.11%EPRXEupraxia Pharmaceuticals-5.17%-4.15%-0.83%-14.96%+81.73%FULCFulcrum Therapeutics-1.93%+3.34%-10.23%-33.11%+26.29%KLRSKalaris Therapeutics+8.07%+1.36%-10.31%-39.65%+521,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 2.00HoldN/AN/AEPRXEupraxia Pharmaceuticals 2.88Moderate Buy$15.00109.50% UpsideFULCFulcrum Therapeutics 2.50Moderate Buy$19.00167.23% UpsideKLRSKalaris Therapeutics 2.75Moderate Buy$15.60198.85% UpsideCurrent Analyst Ratings BreakdownLatest KLRS, EPRX, FULC, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.005/7/2026EPRXEupraxia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/4/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/22/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026EPRXEupraxia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026FULCFulcrum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026KLRSKalaris Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$14.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$225.65M1.92N/AN/A$1.90 per share0.56EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.76 per shareN/AFULCFulcrum Therapeutics$80M5.92N/AN/A$5.00 per share1.42KLRSKalaris TherapeuticsN/AN/AN/AN/A$2.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$429.86M-$1.30N/AN/AN/A-94.39%-46.85%-28.95%5/29/2026 (Estimated)EPRXEupraxia Pharmaceuticals-$38.58M-$1.05N/AN/AN/AN/A-87.56%-51.20%N/AFULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%N/AKLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/ALatest KLRS, EPRX, FULC, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q4 2026CGCCanopy Growth-$0.06N/AN/AN/A$53.43 millionN/A5/12/2026Q1 2026EPRXEupraxia Pharmaceuticals-$0.22-$0.23-$0.01-$0.23N/AN/A5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/A3/19/2026Q4 2025EPRXEupraxia Pharmaceuticals-$0.16-$0.37-$0.21-$0.37N/AN/A3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/A2/24/2026Q4 2025FULCFulcrum Therapeutics-$0.31-$0.31N/A-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.305.344.26EPRXEupraxia Pharmaceuticals0.0219.3115.12FULCFulcrum TherapeuticsN/A34.3334.33KLRSKalaris TherapeuticsN/A12.1912.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%EPRXEupraxia PharmaceuticalsN/AFULCFulcrum Therapeutics89.83%KLRSKalaris Therapeutics66.05%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth0.16%EPRXEupraxia PharmaceuticalsN/AFULCFulcrum Therapeutics7.00%KLRSKalaris Therapeutics68.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150404.12 million403.48 millionOptionableEPRXEupraxia Pharmaceuticals2960.43 millionN/AN/AFULCFulcrum Therapeutics10066.63 million61.97 millionOptionableKLRSKalaris Therapeutics11022.99 million7.33 millionN/AKLRS, EPRX, FULC, and CGC HeadlinesRecent News About These CompaniesKalaris Therapeutics (NASDAQ:KLRS) Given New $25.00 Price Target at Citizens JmpMay 14 at 4:17 AM | americanbankingnews.comKalaris Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 12 at 8:00 AM | globenewswire.comKalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest UpdateMay 1, 2026 | marketbeat.comKalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by AnalystsApril 27, 2026 | marketbeat.comKalaris Therapeutics (NASDAQ:KLRS) Stock Price Down 3.6% - What's Next?April 24, 2026 | marketbeat.comMorgan Stanley initiates coverage of Kalaris Therapeutics (KLRS) with overweight recommendationApril 17, 2026 | msn.comKalaris Therapeutics (NASDAQ:KLRS) CAO Sells 1,915 SharesMarch 24, 2026 | insidertrades.comKalaris Reports Full Year 2025 Financial Results and Provides Business UpdatesMarch 17, 2026 | globenewswire.comSrinivas Akkaraju Buys 479,847 Shares of Kalaris Therapeutics (NASDAQ:KLRS) StockFebruary 18, 2026 | insidertrades.comKalaris Therapeutics: Samsara Opportunity fund buys $5m in sharesFebruary 17, 2026 | investing.comKalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual MeetingJanuary 28, 2026 | markets.businessinsider.comWhy Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Up 10.77%January 9, 2026 | aaii.comAKalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 CatalystsDecember 19, 2025 | seekingalpha.comKalaris Therapeutics announces oversubscribed $50 million financingDecember 18, 2025 | msn.comKalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For GrowthDecember 18, 2025 | seekingalpha.comKalaris Therapeutics raises $50M privatelyDecember 18, 2025 | msn.comKalaris Therapeutics price target raised to $26 from $20 at CitizensDecember 18, 2025 | msn.comKalaris Therapeutics announces initial data from TH103 trialDecember 17, 2025 | msn.comKalaris Therapeutics Announces Oversubscribed $50.0 Million Private PlacementDecember 17, 2025 | globenewswire.comKalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMDDecember 17, 2025 | globenewswire.comWhy Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Up 14.45%December 10, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLRS, EPRX, FULC, and CGC Company DescriptionsCanopy Growth NASDAQ:CGC$1.07 -0.02 (-1.83%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.06 -0.02 (-1.40%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Eupraxia Pharmaceuticals NASDAQ:EPRX$7.16 -0.39 (-5.17%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$7.24 +0.08 (+1.12%) As of 05/14/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Fulcrum Therapeutics NASDAQ:FULC$7.11 -0.14 (-1.93%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$7.03 -0.08 (-1.07%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Kalaris Therapeutics NASDAQ:KLRS$5.22 +0.39 (+8.07%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$5.16 -0.06 (-1.13%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
